Impressive or enduring? The one question that separates a 6x exit from a 12x

Twenty four consecutive quarters of growth in specialty pharmacy is not something that happens by accident. Specialty pharmacy is a market where margin pressure never really lets up, payer relationships shift constantly, and consolidation tends to swallow anyone who isn't prepared for it. A company posting six straight years of compounding growth in that kind of environment is not just having a good run. It is behaving like an anomaly, and anomalies get noticed.

BioPlus was that anomaly, and when the buyers finally showed up to look closely, something in the conversation changed. Instead of asking how fast the company was growing, they started asking how it was actually built. Mark Montgomery understood something that a lot of operators never fully absorb, which is that a great company is not automatically a buyable one. Growth is what earns you the meeting. What happens after that meeting depends almost entirely on structure.

The stage 6 questions

By the time a buyer is deep into diligence, your story has already done its job. What they are testing now is whether the story holds up once someone actually leans on it. That comes down to a small number of questions, and none of them are really about the numbers on the page.

Are you building something a buyer can trust enough to want to own it. Does your company hold together, or even perform better, when things get difficult instead of falling apart. And underneath both of those, the question that gives this stage its name: is what you've built impressive, or is it enduring.

Those two words sound close, but in a buyer's mind they describe entirely different businesses, and only one of them earns a premium multiple.

Impressive gets you noticed, enduring gets you paid

Impressive tends to live in a moment. It's a standout quarter, a marquee client win, a growth chart that looks great in a slide deck. None of that is bad, but none of it is proof either. Enduring is something else. It's a business that produces roughly the same outcome whether the founder is in the building or on a flight somewhere, whether the market is calm or genuinely falling apart around it.

Buyers have paid for ‘impressive’ before, and more than a few of them have watched it fade within a couple of quarters of closing. That experience tends to make people cautious, so they've learned to look past the moment in front of them and ask what's actually running the machine. What they're willing to pay a premium for is a business they can understand, trust, and picture owning for years, not just for the length of a pitch. That difference, more than anything else in the deal, is usually what separates a 6x outcome from a 12x one.

The system was the whole point

If you've been following this series, none of this should feel like it came out of nowhere. Everything before this stage was building toward it. Closing the gap between what your business is actually worth and what a buyer can see from the outside. Building a commercial engine that produces steady, predictable revenue instead of the occasional heroic quarter. Getting sales, marketing, and product working in the same direction instead of past each other. Turning that alignment into momentum that compounds instead of resetting every cycle.

Stage 6 is where all of that effort finally gets paid out. None of the earlier work was really about looking better in a pitch or a data room. It was about becoming the kind of company a buyer wants to own for the long run, and being able to prove that under real scrutiny. You don't create enterprise value during diligence. Diligence just reveals whatever you already built.

The pressure is the point, not the problem

Here's a reframe most CEOs need to hear and rarely do. The board scrutiny, the ticking exit clock, the quiet worry that you're doing an enormous amount without being fully sure it's working. None of that pressure is evidence that something is wrong.

It's evidence that something real is being forged.

Every company that eventually becomes a legend in its industry started out as a hidden hero, quietly doing valuable work the market hadn't yet noticed or figured out how to price. What moves a company from hidden hero to legend is rarely luck or timing. It's structure, built patiently and often under conditions that don't feel rewarding at the time. If the pressure you're under right now feels heavy, that's not a sign you're off track. It might be the clearest sign you're close.

The pattern behind the book

This is the same pattern that shows up again and again in Winning In Healthcare: How the Best Builders Turn Growth Into Enterprise Value. Different founders, different corners of the industry, different problems on the surface, but underneath all of it the same truth: outcomes depend far less on any one person's talent and far more on whether the system beneath them was ever actually built. BioPlus is one story in that book, but it's not an isolated one. It's the throughline.

Most healthcare companies don't fail because the idea was wrong. They fail because no one built the system required to survive success. That line is the reason the book exists, and it's the idea this entire series has been circling since Stage 1.

Impressive is behind you. Enduring is the work ahead. 

You've built something impressive. The real question now is whether it's built to be owned.

If you want an honest read on how your company would hold up under a buyer's scrutiny today, start with a Strategic Fit Call. And if this series has been useful, the full pattern behind it, told through the founders who actually lived it, is in Winning In Healthcare: How the Best Builders Turn Growth Into Enterprise Value, available now on Amazon.